Novo Nordisk AS
(NYSE:NVO)
$
48.18
-0.010 (-0.02%)
Market Cap: 213.09 Bil
Enterprise Value: 232.08 Bil
PE Ratio: 11.69
PB Ratio: 7.00
GF Score: 76/100 
Novo Nordisk A/S at JPMorgan Healthcare Conference Transcript
Jan 13, 2026 / 05:45PM GMT
Release Date Price:
$59.64
(-0.37%)
Richard Vosser
JPMorgan Chase & Co - Analyst
Welcome to the Novo Nordisk session at the 26th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. And it's my great pleasure to welcome the new CEO of Novo, Mike Doustdar. He's been about CEO for about five months and has been spending that time looking at the strategy, revising the strategy. So he's going to go through a few of those thoughts that he's had on the business with a few slides, first of all, and then we're going to have a nice chat.
Maziar Doustdar;S;President and Chief Executive Officer
Novo Nordisk A
/-
Hope so.
Richard Vosser
JPMorgan Chase & Co - Analyst
So Mike with that, over to you.
Maziar Doustdar;S;President and Chief Executive Officer
Novo Nordisk A
/-
Thanks so much.
Richard Vosser;
JPMorgan Chase & Co - Analyst
Welcome.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers